

Editorial on Nutrition

Cell-free DNA methylation as liquid biopsy for the assessment of fibrosis in patients with nonalcoholic steatohepatitis: a gap between innovation and implementation

Silvia Sookoian¹, Carlos J. Pirola^{1,2}

¹Department of Clinical and Molecular Hepatology, ²Department of Molecular Genetics and Biology of Complex Diseases, Institute of Medical Research A Lanari-IDIM, University of Buenos Aires-National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina

Correspondence to: Silvia Sookoian, MD, PhD. Instituto de Investigaciones Médicas, IDIM-CONICET, Combatientes de Malvinas 3150, CABA-1427, Argentina. Email: sookoian.silvia@lanari.fmed.uba.ar; Carlos J. Pirola, PhD. Instituto de Investigaciones Médicas, IDIM-CONICET, Combatientes de Malvinas 3150, CABA-1427, Argentina. Email: pirola.carlos@lanari.fmed.uba.ar.

Provenance: This is an invited Editorial commissioned by Editor-in-Chief Yilei Mao (Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China).

Comment on: Hardy T, Zeybel M, Day CP, *et al.* Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. *Gut* 2016. [Epub ahead of print].

Submitted Dec 02, 2016. Accepted for publication Dec 19, 2016.

doi: 10.21037/hbsn.2017.01.07

View this article at: <http://dx.doi.org/10.21037/hbsn.2017.01.07>

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease whose prevalence has reached global epidemic proportions, both in adults and children (1). There is consistent clinical and epidemiological evidence supporting the assertion that NAFLD may progress from a benign histological stage characterized by hepatic triglyceride accumulation, also known as simple steatosis, to a more severe histological picture characterized by liver cell injury, a mixed inflammatory lobular infiltrate, and variable fibrosis named nonalcoholic steatohepatitis (NASH) (1). Numerous factors influence the disease severity and progression, including genetic predisposition (2) and aberrant tissue-specific DNA methylation modifications that have been observed not only in the nuclear (1,3,4) but the mitochondrial genome as well (5). Presently, DNA methylation is one of the most extensively studied epigenetic modifications in eukaryotes consisting of a methyl group covalently added to a cytosine, yielding 5-methylcytosine (5mC).

In addition, robust evidence indicates that the progression of NAFLD is associated with both mitochondrial dysfunction (6) and genetic diversity in mitochondrial genes that encode for members of the oxidative phosphorylation (OXPHOS) chain (7). Furthermore, environmental factors such alcohol consumption, even in light or

moderate amounts (8), as well as diet and lifestyle (9), are also implicated in the development of a more aggressive histological phenotype. Interestingly, available evidence indicates that lifestyle factors such as exercise may modify epigenetic marks (5).

The histological diagnosis of NASH is based exclusively on liver biopsy, which is currently the gold standard for determining the disease diagnosis and prognosis accurately (10). Unfortunately, this method is not only prone to patient complications, but is also expensive, while requiring extensive training and advanced skills. In the last decade, numerous imaging methods (11) as well as circulating molecular biomarkers, including epigenetic factors such as miRNAs (12), have been proposed, opened up the potential for the non-invasive diagnosis of liver fibrosis and advanced NASH. In fact, we have demonstrated that circulating miRNAs, in particular miR-122, not only mirror histological and molecular events occurring in the liver but have a reliable predictive power, allowing simple steatosis and NASH to be distinguished (12). In addition, we observed that NAFLD has a distinctive circulating miRNA profile associated with a global dysmetabolic disease-state and cardiovascular risk (12).

The evolving implementation of high-throughput OMICs profiling of biological samples—which includes

genetic variation, metabolomics, transcriptomics, proteomics, metagenomics and epigenomics—has directly influenced the rate of biomarker discovery. Unfortunately, integration of this knowledge into the healthcare system is time consuming, while also facing other tremendous challenges that must be overcome.

Hardy and coworkers have recently published a proof-of-concept study involving a small sample of patients, which findings suggest that plasma DNA methylation signatures might reflect the molecular pathology associated with fibrotic liver disease (13). Specifically, the authors showed that differential DNA methylation at two CpG sites in the promoter of peroxisome proliferator-activated receptor γ ($PPAR\gamma$) can be detected within the pool of cell-free DNA (cfDNA) of patients with end-stage liver disease, and may potentially allow stratifying patients with NAFLD into those with mild versus severe fibrosis (13). While interesting and promising, these findings deserve some reflections.

The role of epigenetics in the biology of NAFLD

Epigenetic mechanisms play a critical role in the reprogramming machinery of hepatocytes and other liver cells as a means of adapting to the stressful environment caused by the abnormal accumulation of fat and its consequences, including inflammation and oxidative stress (14). Robust evidence yielded by human studies has demonstrated that NAFLD severity is associated with a consistent pattern in the methylome and transcriptome of the liver tissue characterized by hypermethylation and down-regulation of genes involved in metabolic function (3,5,15) versus hypomethylation and up-regulation of genes involved in liver regeneration, tumorigenesis and tissue repair (15). This damage-associated molecular pattern is translated into a disease phenotype characterized by increased fibrogenesis and metabolic deregulation.

Tissue-specific methylation changes can be detected in circulation: the attractive concept of liquid biopsy

As mentioned earlier, the distinguishing epigenetic modifications associated with NAFLD progression are tissue-specific, as they are observed either in the liver of the affected patients or other tissues, while still having a direct effect on the liver functioning. Whether liver-related aberrant DNA methylation patterns can be directly assessed in the blood by exploring cfDNA, which would

enable accurate stratification of liver fibrosis associated with NASH, remains to be demonstrated in large cohorts.

A remarkable study, as a part of which the researchers performed a genome-wide bisulfite sequencing of plasma cfDNA, yielded findings indicating that white blood cells are the predominant contributors to the circulating DNA pool, while cells derived from the liver are sufficiently represented as well (16). This finding certainly supports the potential for the use of methylation modifications in cfDNA as liquid biopsy in the diagnosis and prognosis of liver diseases, hepatocellular carcinoma in particular (16). Nevertheless, the finding suggesting that two promoter CpG sites in $PPAR\gamma$ become hypermethylated as fibrosis severity increases, where this observation served as a surrogate of specific changes occurring in the liver tissue (13), deserves some other considerations. First, cfDNA consists of a pool of mixture DNA released from different tissues of the body, usually as a byproduct of dead—mostly apoptotic—cells. Hence, the question of whether NASH-associated significant fibrosis is linked to significant hepatocyte cell death that in turn explains the source of cfDNA remains unanswered in the study conducted by Hardy *et al.* Unfortunately, the authors did not present any morphologic or circulating biomarkers of cell death—for instance, caspase-generated cytokeratin-18 fragments (CK-18)—in association with their findings. Extant literature provides some evidence supporting the notion that genetic diversity in genes encoding the ten-eleven-translocation (TET) family of proteins—which are responsible for catalyzing the conversion of 5-methylcytosine to 5-hmC—is involved in the epigenetic regulation of programmed liver-cell death in patients with NASH (4). Thus, the connection between advanced fibrosis and epigenetic modifications that eventually feed the pool of cfDNA in patients with NASH is still not fully elucidated.

Second, the selection of $PPAR\gamma$ as the candidate gene for exploring surrogate liver DNA methylation changes in the blood represents a significant challenge due to the high expression levels of this gene in many different tissues that are strongly associated with the biology of NAFLD and related co-morbidities. For example, under physiological conditions, $PPAR\gamma$ exhibits the highest expression in adipose tissue, and is lower in skeletal muscle, spleen, heart and the liver; however, $PPAR\gamma$ is also detectable in placenta, lung and ovary. A comprehensive list of tissues in which $PPAR\gamma$ is expressed, as well as the magnitude of its expression, is shown in *Table 1*. Interestingly, in disease states, including the metabolic syndrome and obesity—two conditions

Table 1 Gene expression analysis of human *PPAR γ* (ENSG00000132170) in physiological conditions

Tissue	Rank score [#]	Source	Developmental stage(s)
Adipose tissue	2.17e3	Affymetrix, EST, RNA-Seq	5 stages
Subcutaneous adipose tissue	2.64e3	Affymetrix	3 stages
Blood	3.09e4	Affymetrix	5 stages
sigmoid colon	4.85e3	Affymetrix	3 stages
Layer of synovial tissue	4.72e3	Affymetrix	7 stages
Colon	5.37e3	Affymetrix, EST, RNA-Seq	7 stages
Prostate gland	5.38e3	Affymetrix, EST, RNA-Seq	3 stages
Heart	6.05e3	Affymetrix, EST, RNA-Seq	4 stages
Lymph node	6.23e3	RNA-Seq	1 stage
Adrenal gland	6.42e3	Affymetrix, RNA-Seq	2 stages
Thyroid gland	7.59e3	Affymetrix, RNA-Seq	4 stages
Mucosa of sigmoid colon	7.77e3	Affymetrix	1 stage
Omental fat pad	7.84e3	Affymetrix	1 stage
Liver	7.87e3	Affymetrix, RNA-Seq	5 stages*
Mammalian vulva	8.45e3	Affymetrix	1 stage
Female gonad	8.99e3	Affymetrix, EST, RNA-Seq	9 stages
Jejunal mucosa	9.61e3	Affymetrix	1 stage
Skeletal muscle tissue	1.10e4	RNA-Seq	1 stage
Duodenum	1.23e4	Affymetrix	1 stage
Coronary artery	1.27e4	Affymetrix	1 stage

Data was retrieved from the Bgee database, available at <http://bgee.org/> that compares gene expression patterns from multiple data types (RNA-Seq, Affymetrix, *in situ* hybridization, and EST data) in different developmental stages. The Bgee database consists of curate normal-healthy expression (e.g., no gene knock-out, no treatment, no disease), to provide a comparable reference of normal gene expression data. [#], rank scores: rank scores of expression calls are normalized across genes, conditions and species; *, developmental stage(s) for liver tissue: HsapDv:0000090, 25 to 44-year-old human stage (human); HsapDv:0000092, human middle-aged stage (human); HsapDv:0000089, young adult stage (human); HsapDv:0000197, third LMP month human stage (human); UBERON:0000104, life cycle. Sources of raw data: Affymetrix data, ArrayExpress; EST data, UniGene; RNA-Seq data, GEO. *PPAR γ* , peroxisome proliferator-activated receptor γ .

strongly associated with advanced fibrosis in NASH—*PPAR γ* is hypermethylated in adipocytes (17). Furthermore, recent evidence indicates that transient *PPAR γ* promoter methylation occurs after common events of ordinary life, for instance, physical exercise or caffeine consumption (18). Hence, dynamic changes associated with epigenetic modifications may specifically jeopardize the selection of *PPAR γ* as the “candidate gene” for use as a biomarker of liver fibrosis.

Challenges: translating laboratory work into the clinical practice

The presence of cfDNA in the circulating compartment was demonstrated three decades ago (19), leading to the emergence of liquid biopsy. The applications of this innovative concept in the clinical setting are summarized in *Table 2*. However, the implementation of cfDNA methylation as a non-invasive molecular tool for the

diagnosis of fibrosis imposes tremendous analytical and technical challenges because cfDNA is not only highly fragmented (~170–500 bp) but also circulates at

very low concentrations (1.8–44 ng/mL). The fact that exploration of DNA methylation signatures requires a previous step of DNA bisulfitation or other complex and protracted techniques, such as 5mC-containing DNA immunoprecipitation and sequencing, imposes further obstacles to the adoption of this method. The three main pitfalls to overcome before cfDNA methylation could be employed as biomarker of fibrosis are illustrated in *Figure 1*. Available evidence suggests that a considerable gap between innovation and implementation still exists, preventing definitive affirmation that plasma DNA methylation signatures reflect the molecular pathology associated with fibrotic liver disease. Nonetheless, this is a promising horizon toward which further research efforts should be directed.

Table 2 Liquid biopsy of circulating nucleotide acids in the clinical setting

Detection of tumor mutations in circulating tumor DNA
Molecular cytogenetic analysis
DNA methylation of genes mutated in tumors
Genetic alterations in tumors: microsatellite instability and loss of heterozygosity
Detection of fetal genomic abnormalities




Figure 1 Obstacles to translating the concept of cell free DNA (cfDNA) methylation into the clinical setting for the stratification of liver fibrosis. This image illustrates the three main pitfalls that must be overcome before cfDNA methylation could be employed as a fibrosis biomarker, namely: (I) the ultimate source of cfDNA should be clearly demonstrated, as cfDNA circulates as a pool of DNA originating from dead cells from the entire body, particularly blood cells; (II) cfDNA is highly fragmented (~170–500 bp) and circulates at very low levels; and (III) exploration of aberrant patterns of DNA methylation in cfDNA requires large amounts of DNA to guarantee proper bisulfite conversion of DNA.

Acknowledgements

Funding: This study was partially supported by grants PICT 2014-0432, PICT 2014-1816 and PICT 2015-0551 (Agencia Nacional de Promoción Científica y Tecnológica, FONCyT). S Sookoian and CJ Pirola belong to Consejo Nacional de Investigaciones Científicas (CONICET).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Brunt EM, Wong VW, Nobili V, et al. Nonalcoholic fatty liver disease. *Nat Rev Dis Primers* 2015;1:15080.
2. Sookoian S, Pirola CJ. The genetic epidemiology of nonalcoholic fatty liver disease: toward a personalized medicine. *Clin Liver Dis* 2012;16:467-85.
3. Sookoian S, Rosselli MS, Gemma C, et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1 α promoter. *Hepatology* 2010;52:1992-2000.
4. Pirola CJ, Scian R, Gianotti TF, et al. Epigenetic Modifications in the Biology of Nonalcoholic Fatty Liver Disease: The Role of DNA Hydroxymethylation and TET Proteins. *Medicine (Baltimore)* 2015;94:e1480.
5. Pirola CJ, Gianotti TF, Burgueño AL, et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. *Gut* 2013;62:1356-63.
6. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology* 2001;120:1183-92.
7. Sookoian S, Flichman D, Scian R, et al. Mitochondrial genome architecture in non-alcoholic fatty liver disease. *J Pathol* 2016;240:437-49.
8. Sookoian S, Flichman D, Castaño GO, et al. Mendelian randomisation suggests no beneficial effect of moderate alcohol consumption on the severity of nonalcoholic fatty liver disease. *Aliment Pharmacol Ther* 2016;44:1224-34.
9. Hannah WN Jr, Harrison SA. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. *Dig Dis Sci* 2016;61:1365-74.
10. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012;142:1592-609.
11. Hannah WN Jr, Harrison SA. Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology* 2016;64:2234-43.
12. Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. *Gut* 2015;64:800-12.
13. Hardy T, Zeybel M, Day CP, et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. *Gut* 2016. [Epub ahead of print].
14. Sookoian S, Pirola CJ. NAFLD. Metabolic make-up of NASH: from fat and sugar to amino acids. *Nat Rev Gastroenterol Hepatol* 2014;11:205-7.
15. Murphy SK, Yang H, Moylan CA, et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. *Gastroenterology* 2013;145:1076-87.
16. Sun K, Jiang P, Chan KC, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. *Proc Natl Acad Sci U S A* 2015;112:E5503-12.
17. Fujiki K, Kano F, Shiota K, et al. Expression of the peroxisome proliferator activated receptor gamma gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes. *BMC Biol* 2009;7:38.
18. Barrès R, Yan J, Egan B, et al. Acute exercise remodels promoter methylation in human skeletal muscle. *Cell Metab* 2012;15:405-11.
19. Shapiro B, Chakrabarty M, Cohn EM, et al. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. *Cancer* 1983;51:2116-20.

Cite this article as: Sookoian S, Pirola CJ. Cell-free DNA methylation as liquid biopsy for the assessment of fibrosis in patients with nonalcoholic steatohepatitis: a gap between innovation and implementation. *HepatoBiliary Surg Nutr* 2017;6(2):117-121. doi: 10.21037/hbsn.2017.01.07